Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25371573 | 1.00 | KCNH2 (0.35) | KCNH2SCN5ACACNA1ICTSKGRM2 | |
| SCHEMBL25370731 | 1.00 | KCNH2 (0.35) | KCNH2SCN5ACACNA1ICTSKGRM2 | |
| SCHEMBL26066118 | 0.89 | KCNH2 (0.40) | KCNH2SCN5ACACNA1ICTSKGRM2 | |
| SCHEMBL26066117 | 0.89 | KCNH2 (0.40) | KCNH2SCN5ACACNA1ICTSKGRM2 | |
| SCHEMBL26066112 | 0.89 | KCNH2 (0.40) | KCNH2SCN5ACACNA1ICTSKGRM2 | |
| SCHEMBL25369931 | 0.88 | EBP (0.38) | KCNH2CTSKOPRM1OPRL1 | |
| SCHEMBL30567055 | 0.86 | CTSK (0.35) | CTSKOPRM1OPRL1 | |
| SCHEMBL25373929 | 0.86 | CTSK (0.35) | CTSKOPRM1OPRL1 | |
| SCHEMBL25369016 | 0.86 | CTSK (0.35) | CTSKOPRM1OPRL1 | |
| SCHEMBL25372158 | 0.84 | CTSK (0.38) | CTSKOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | claimed |
| EP-4482587-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4482587-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | KCNH2 4874/4885SCN5A 3754/4885CACNA1I 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.